down arrow

Enlivex Therapeutics Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011319527
USD
1.16
0.21 (21.53%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.061.18

52 Week

0.832.10
Valuation
Technical
Day's Volume

CASH

940.19 k

Shareholding (Mar 2025)

FII

0.58%

Held by 11 FIIs

DII

99.37%

Held by 0 DIIs

Promoter

0.00%

How big is Enlivex Therapeutics Ltd.?

22-Jun-2025

As of Jun 18, Enlivex Therapeutics Ltd. has a market capitalization of 24.57 million and reported net sales of 0.00 million with a net profit of -14.33 million over the last four quarters. Shareholder's funds are 23.59 million, and total assets amount to 27.69 million.

As of Jun 18, Enlivex Therapeutics Ltd. has a market capitalization of 24.57 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -14.33 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 23.59 million and total assets amounting to 27.69 million.

Read More

What does Enlivex Therapeutics Ltd. do?

22-Jun-2025

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage company specializing in cell immunotherapy to develop treatments for immune hyper-responses. It has a market cap of $24.57 million and reported a net loss of $3 million in Q1 2025.

Overview:<BR>Enlivex Therapeutics Ltd. is an Israel-based clinical-stage company focused on specialized cell immunotherapy within the Pharmaceuticals & Biotechnology industry, aiming to develop an allogeneic drug pipeline for rebalancing immune hyper-responses.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 24.57 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: -69.45% <BR>Price to Book: 1.19 <BR><BR>Contact Details:<BR>Address: 14 Einstein St., NESS-ZIONA None: 7403618 <BR>Tel: 972 2 6708072 <BR>Fax: 972 2 6708070 <BR>Website: https://www.enlivex.com/

Read More

Who are in the management team of Enlivex Therapeutics Ltd.?

22-Jun-2025

As of March 2022, the management team of Enlivex Therapeutics Ltd. includes Executive Chairman Mr. Shai Novik and Directors Mr. Michel Habib, Mr. Baruch Halpert, Dr. Bernhard Kirschbaum, Dr. Hyun Gyu Lee, and Mr. Sangwoo Lee.

As of March 2022, the management team of Enlivex Therapeutics Ltd. includes the following individuals:<BR><BR>- Mr. Shai Novik, who serves as the Executive Chairman of the Board.<BR>- Mr. Michel Habib, who is a Director.<BR>- Mr. Baruch Halpert, who is also a Director.<BR>- Dr. Bernhard Kirschbaum, who holds the position of Director.<BR>- Dr. Hyun Gyu Lee, who is a Director.<BR>- Mr. Sangwoo Lee, who is a Director.

Read More

Is Enlivex Therapeutics Ltd. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, Enlivex Therapeutics Ltd. shows a mildly bullish trend, supported by daily moving averages and KST indicators, despite underperforming the S&P 500 with year-to-date and one-year returns of -10.26% and -32.26%, respectively.

As of 18 August 2025, the technical trend for Enlivex Therapeutics Ltd. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness, while the weekly MACD is mildly bearish and the Bollinger Bands are bearish. The KST shows bullishness on both weekly and monthly time frames, which adds some strength to the mildly bullish outlook. However, the overall performance has been poor compared to the S&P 500, with a year-to-date return of -10.26% versus the S&P 500's 12.22%, and a one-year return of -32.26% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 25 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.02

stock-summary
Return on Equity

-68.74%

stock-summary
Price to Book

1.30

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.43%
0%
9.43%
6 Months
23.36%
0%
23.36%
1 Year
-10.77%
0%
-10.77%
2 Years
-35.56%
0%
-35.56%
3 Years
-73.99%
0%
-73.99%
4 Years
-82.15%
0%
-82.15%
5 Years
-89.82%
0%
-89.82%

Enlivex Therapeutics Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Enlivex Therapeutics Ltd. technically bullish or bearish?

As of 18 August 2025, the technical trend for Enlivex Therapeutics Ltd. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness, while the weekly MACD is mildly bearish and the Bollinger Bands are bearish. The KST shows bullishness on both weekly and monthly time frames, which adds some strength to the mildly bullish outlook. However, the overall performance has been poor compared to the S&P 500, with a year-to-date return of -10.26% versus the S&P 500's 12.22%, and a one-year return of -32.26% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-19.89%
EBIT to Interest (avg)
-12.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.08%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.12
EV to EBIT
-0.18
EV to EBITDA
-0.18
EV to Capital Employed
2.65
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1509.00%
ROE (Latest)
-69.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.05%)

Foreign Institutions

Held by 11 Foreign Institutions (0.58%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 38.71% vs 54.41% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.00",
          "val2": "-2.80",
          "chgp": "-7.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.90",
          "val2": "-3.10",
          "chgp": "38.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 48.45% vs 6.43% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.00",
          "val2": "-24.10",
          "chgp": "37.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.00",
          "val2": "-29.10",
          "chgp": "48.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.00
-2.80
-7.14%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.90
-3.10
38.71%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 38.71% vs 54.41% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.00
-24.10
37.76%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.00
-29.10
48.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 48.45% vs 6.43% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Enlivex Therapeutics Ltd. stock-summary
stock-summary
Enlivex Therapeutics Ltd.
Pharmaceuticals & Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.
Company Coordinates stock-summary
Company Details
14 Einstein St. , NESS-ZIONA None : 7403618
stock-summary
Tel: 972 2 6708072
stock-summary
https://www.enlivex.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."